MedTrace Logo

Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)

NCT02083406 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-03-23

Study results available
· View outcomes & findings →

Summary

A single dose study to investigate how different formulations of OZ439 co-administered with PQP tablest are processed by the body when taken without food

Conditions

Interventions

DRUG

800mg OZ439 prototype formulation 1

DRUG

800mg OZ439 prototype formulation 2

DRUG

800mg OZ439 prototype formulation 3

DRUG

960mg PQP

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • Medicines for Malaria Venture

    lead OTHER

Principal Investigators

  • Jo Collier, MBChB FFPM · Quotient Clinical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083406 on ClinicalTrials.gov